FindTrial
Sign In

Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

DRUG3 trials

Sponsors

University of Leipzig, Janssen - Cilag International, Kura Oncology Inc.

Conditions

Acute Myeloid LeukemiaAcute myeloid leukemiaHigh-risk Myelodysplastic neoplasiaNPM1-m and KMT2A-r Acute Myeloid Leukemia

Phase 1

A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
Active, not recruitingCTIS2023-506582-58-00
Janssen - Cilag InternationalAcute Myeloid Leukemia
Start: 2022-07-21Target: 86Updated: 2025-10-03

Phase 2

Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)
CompletedCTIS2022-502040-13-00
University of LeipzigAcute myeloid leukemia, High-risk Myelodysplastic neoplasia
End: 2024-02-08Target: 108Updated: 2023-07-18

Phase 3

Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
Not yet recruitingCTIS2025-521314-25-00
Kura Oncology Inc.NPM1-m and KMT2A-r Acute Myeloid Leukemia
Target: 280Updated: 2026-02-23